<DOC>
	<DOCNO>NCT01071473</DOCNO>
	<brief_summary>This application propose prospective , single arm feasibility clinical trial 12-week period combine endurance resistance training survivor childhood cancer treat doxorubicin and/or daunorubicin impair cardiac function . Baseline post intervention imaging , laboratory , neuropsychological evaluation use determine effect intervention body composition , serum lipid profile , exercise tolerance , neurocognitive functioning . Participants call weekly monitor compliance intervention . Incentives give interval trial optimize compliance intervention .</brief_summary>
	<brief_title>Resistance Aerobic Exercise Subclinical Anthracycline Cardiomyopathy</brief_title>
	<detailed_description>This study evaluate feasibility 12-week exercise intervention cardiac function survivor childhood cancer treat anthracyclines know cardiomyopathy . As secondary objective , study document effect 12-week exercise intervention exercise tolerance , determine measurement peak VO2 peak exercise workload , shorten fraction , ejection fraction , leave ventricular wall thickness , assess impact intervention neurocognitive functioning survivor childhood cancer treat anthracyclines know cardiomyopathy .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Treated St. Jude Children 's Research Hospital ( SJCRH ) Ages 0 17 year time treatment Treated type cancer ≥ 10 year date diagnosis ≥ 2 year completion active cancer therapy ≥ 18 year age Treated doxorubicin and/or daunorubicin ( cumulative dose ) Ejection fraction &lt; 55 % without medication Does currently meet Centers Disease Control ( CDC ) recommendation exercise adult Ejection fraction ≤ 40 % Pregnant female ( Positive Urine pregnancy Test ) . History congenital heart disease History myocardial infarction History acute coronary syndrome Individuals pacemaker implant defibrillator History radiation therapy include part heart ≥1mm Jpoint depression ( depression measure 80 msec Jpoint ) ST segment flat downsloping majority complex ECG lead except AVR exercise test . All patient classify use recommendation American Heart Association . Patients find Class A , C Class D eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Childhood cancer</keyword>
	<keyword>Anthracyclines</keyword>
	<keyword>Cardiomyopathy</keyword>
</DOC>